mRNA 1893
Alternative Names: mRNA-1893; Zika virus vaccine - Moderna TherapeuticsLatest Information Update: 02 Sep 2024
At a glance
- Originator Moderna Therapeutics
- Class RNA vaccines; Zika virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Zika virus infection
Most Recent Events
- 26 Jul 2024 Moderna Tx completes a phase II trial in in Zika virus infection (Prevention) in USA, Puerto Rico (Parenteral) (NCT04917861)
- 15 Jun 2021 Moderna Therapeutics plans a phase II trial for Zika virus infection (Prevention) in USA and Puerto Rico (Parenteral, Injection) (NCT04917861)
- 08 Jun 2021 Phase-II clinical trials in Zika virus infection (Prevention) in USA, Puerto Rico (Parenteral) (NCT04917861)